welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Evaluation of Muscle miRNA as Biomarkers in Dystrophinopathies
study id #: NCT02109692
condition: Muscular Dystrophies, Becker Muscular Dystrophy, Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD), caused by mutations in the DMD gene, is the most common and most severe progressive dystrophy of the child. Although the development is rapidly progressive, there is variability in the severity of the disease between DMD patients that do not correlate with the type of mutations in the DMD gene. There are no easily measurable biomarkers for monitoring the DMD or moderate form of the disease, Becker muscular dystrophy (BMD). MicroRNAs (miRNAs) are involved in most cellular processes, and their expression pattern is a signature of the state of a cell. They represent a potential class of diagnostic and prognostic biomarkers. Some are specific for the skeletal myogenesis, and changes in their pattern of expression are associated with muscle diseases including muscular dystrophy. The levels of muscle- specific miRNAs are indeed greatly increased in the serum of DMD and BMD compared to control patients. The main objective of this is to validate the use of serum muscle-derived microRNAs as biomarkers of DMD patients (compared with healthy subjects). Secondary objectives are i) to investigate the relationship between circulating levels of these miRNAs and the severity of the dystrophinopathy (DMD vs BMD) and also the progression of the disease (longitudinal study), ii) to assess the specificity of these markers for dystrophinopathy (comparison with other patients with muscular dystrophy), iii) to test candidate miRNAs recently identified but not yet analyzed in the serum of patients. Clinical data and samples will be recorded at each regular consultation. miRNA levels will be quantified using Real Time Quantitative RT-PCR.
intervention: blood sample
mechanism of action: No pharmaceutical intervention
last updated: November 22, 2018
start date: May 19, 2014
estimated completion: November 2018
phase of development: N/A
size / enrollment: 186
- Quantity of serum muscle-derived microRNAs of DMD patients [Time Frame: up to 12 months]
To validate the use of serum muscle-derived microRNAs as biomarkers of DMD patients (compared with healthy subjects)
- severity of the dystrophinopathy [Time Frame: up to 36 months]
to investigate the relationship between circulating levels of these miRNAs and the severity of the dystrophinopathy
- progression of the disease [Time Frame: up to 36 months]
to investigate the relationship between circulating levels of these miRNAs and the progression of the disease
- specificitiy of miRNA for distrophinopathy [Time Frame: up to 36 months]
to assess the specificity of these markers for dystrophinopathy (comparison with other patients with muscular dystrophy)
• Patient suffers from dystrophinopathy or other muscle dystrophy
• Healthy volunteers
• signed informed consent
• social insurance
patients or parents have not signed the informed consent
Study of Ataluren for Previously Treated Patients With nmDBMD in Europe, Israel, Australia, and CanadaDuchenne/Becker muscular dystrophy (DBMD...
Effect of Modulating the nNOS System on Cardiac, Muscular and Cognitive Function in Becker Muscular Dystrophy Patien...This study is done to evaluate whether t...
Roche Letter to the Duchenne CommunityBy now, many have heard about Pfizer's d...
PhaseOut DMD: a Phase 2, proof of concept, clinical study of utrophin modulation with ezutromidThis study investigates the hypothesis t...
Clay Matthews Supports Duchenne Muscular Dystrophy and First Approved Treatmenthttps://www.youtube.com/watch?v=WPu5pGEF...
Pfizer doses first patient using investigational mini-dystrophin gene therapy for the treatment of Duchenne muscular...Pfizer Inc. has initiated a Phase 1b cli...
Santhera to present novel data highlighting the clinical relevance of peak expiratory flow as predictor of disease p...Santhera Pharmaceuticals announces that ...